Effect of antiviral therapy on 3-year recurrence and prognosis of hepatocellular carcinoma after curative radiofrequency ablation

Table 1 Baseline data of hepatitis B cirrhosis-related hepatocellular carcinoma post radiofrequency treatment with entecavir, tenofovir disoproxil fumarate and tenofovir alafenamide fumarate, n (%)

Characteristics	ETV	TDF	TAF	P value
n	191	76	52
Gender				0.945
Male	151 (79.06)	61 (80.26)	42 (80.77)
Female	40 (20.94)	15 (19.74)	10 (19.23)
Age (years)	60.13 ± 8.05	57.58 ± 8.27	60.12 ± 8.69	0.067
Family history of CHB				0.985
POS	57 (29.84)	23 (30.26)	16 (30.77)
NEG	134 (70.16)	53 (69.74)	36 (69.23)
Family history of HCC				0.996
POS	30 (15.71)	12 (15.79)	8 (15.38)
NEG	161 (84.29)	64 (84.21)	44 (84.62)
Smoking				0.992
POS	60 (31.41)	24 (31.58)	16 (30.77)
NEG	131 (68.59)	52 (68.42)	36 (69.23)
Hyperlipidemia				0.957
POS	32 (16.75)	12 (15.79)	8 (15.38)
NEG	159 (83.25)	64 (84.21)	44 (84.62)
Diabetes				0.999
POS	40 (20.94)	16 (21.05)	11 (21.15)
NEG	151 (79.06)	60 (78.95)	41 (78.85)
BMI (kg/m2)	23.12 ± 2.68	22.54 ± 2.27	22.79 ± 2.14	0.168
WBC (× 109/L)	3.98 ± 1.67	4.07 ± 1.55	3.96 ± 1.60	0.909
HGB (g/L)	134.78 ± 19.09	137.68 ± 19.8	133.43 ± 21.03	0.417
PLT (× 109/L)	83.00 (60.00-132.75)	95.00 (63.75-145.00)	94.00 (61.05-122.00)	0.474
INR	1.16 ± 0.18	1.14 ± 0.14	1.14 ± 0.22	0.565
ALB (g/L)	41.19 ± 5.47	41.68 ± 5.62	41.92 ± 4.92	0.618
ALT (U/L)	20.00 (16.00-27.50)	27.00 (22.00-38.25)	20.00 (16.00-30.00)	< 0.001
AST (U/L)	25.00 (20.00-33.00)	30.50 (25.00-43.25)	22.50 (19.00-30.00)	< 0.001
ALP (U/L)	88.31 ± 33.02	102.16 ± 39.23	82.67 ± 32.96	0.002
GGT (U/L)	31.00 (23.00-50.00)	47.00 (27.50-74.50)	35.00 (25.00-48.00)	0.005
TBIL (μmol/L)	15.70 (12.30-25.40)	14.45 (12.18-23.25)	17.25 (12.00-20.92)	0.795
eGFR (mL/min/1.73 m2)	94.67 ± 14.35	95.31 ± 12.18	96.16 ± 14.23	0.638
HBsAg (lgIU/mL)	2.02 (1.43-2.35)	2.01 (1.21-2.27)	2.26 (1.63-2.92)	0.566
HBeAg				0.910
POS	48 (25.13)	20 (26.31)	15 (28.85)
NEG	143 (74.87)	56 (73.69)	37 (71.15)
HBV DNA				0.045
POS	27 (14.14)	21 (27.63)	11 (21.15)
NEG	164 (85.86)	55 (72.37)	41 (78.85)
AFP (ng/mL)	7.61 (2.90-52.10)	11.99 (3.58-36.70)	7.81 (3.19-89.35)	0.595
Child-Pugh
A	181 (94.76)	71 (92.42)	49 (94.23)	0.764
B	10 (5.24)	5 (6.58)	3 (5.77)
BCLC
0	167 (87.43)	67 (88.16)	45 (86.54)	0.672
A	24 (12.57)	9 (11.84)	7 (13.48)

HCC: Hepatocellular carcinoma; ETV: Entecavir; TDF: Tenofovir disoproxil fumarate; TAF: Tenofovir alafenamide fumarate; BMI: Body mass index; WBC: White blood cell; ALB: Albumin; ALT: Alanine aminotransferase; HGB: Hemoglobin; PLT: Platelet; TBIL: Total bilirubin; eGFR: Estimated glomerular filtration rate; INR: International normalized ratio; ALP: Alkaline phosphatase; AFP: Alpha-fetoprotein; AST: Aspartate aminotransferase; GGT: γ-glutamyl transpeptidase; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; NEG: Negative; POS: Positive; HBV: Hepatitis B virus; BCLC: Barcelona Clinic Liver Cancer.